The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...
Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...
The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and ...
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...
If you’ve been diagnosed with major depressive disorder, seasonal affective depression or any other type of depression, your ...
In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.